[1] World Health Organization.Hepatitis B.(2022-06-24)[2023-06-13].https://www.who.int/zh/news-room/fact-sheets/detail/hepatitis-b.
[2] 中华医学会血液学分会,中国抗癌协会淋巴瘤专业委员会,中华医学会肝病学分会.中国淋巴瘤合并HBV感染患者管理专家共识.中华血液学杂志,2013,34(11):988-993.
[3] 李新慧,吴超.乙肝病毒再激活的危险因素和防治方案.中华临床医师杂志(电子版),2011,5(1):182-185.
[4] 李立.糖皮质激素诱导中核苷类抗病毒药预防治疗的HBV再激活临床回顾性研究.中西医结合心血管病电子杂志,2020,1:84.
[5] 张倩,韩涛.肝衰竭前期预警指标的研究进展.中华肝脏病杂志,2020,28(4):292-298.
[6] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版).中华传染病杂志,2019,27(1):18-26.
[7] 中国中西医结合学会.慢加急性肝衰竭中西医结合诊疗专家共识.临床肝胆病杂志,2021,40(9):2045-2053.
[8] Sun LJ,Yu JW,Zhao YH,et al.Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure.J Gastroenterol Hepatol,2010,25(3):583-590.
[9] 程能能.我国首个原研口服抗HBV药物TMF结构优势解读—神奇的甲基化.肝脏,2021,26(12):1303-1305.
[10] Broquetas T,Carrión JA.Current perspectives on nucleos(t)ide analogue therapy for the long-term treatment of hepatitis B virus.Hepat Med,2022,14:87-100.
[11] Ma XF,Liu SS,Wang MK,et al.Tenofovir alafenamide fumarate, tenofovir disoproxil fumarate and entecavir: which is the most effective drug for chronic hepatitis B? A systematic review and meta-analysis.J Clin Transl Hepatol,2021,9(3):335-344.
[12] Liu ZH,Jin QL,Zhang YX,et al.Randomised clinical trial:48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B.Aliment Pharmacol Ther,2021,54(9):1134-1149 .
[13] 李亚萍,崔丹丹,苟国娥,等.艾米替诺福韦治疗慢性乙型肝炎患者的早期疗效:一项真实世界多中心临床研究.肝脏,2023,28(1):100-104.
[14] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2022年版).中华传染病杂志,2023,41(1):3-28. |
